Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Cynthia B Sinha"'
Autor:
Anirudh Veludhandi, Diana Ross, Cynthia B Sinha, Courtney McCracken, Nitya Bakshi, Lakshmanan Krishnamurti
Publikováno v:
JMIR Formative Research, Vol 5, Iss 10, p e30093 (2021)
BackgroundIndividuals living with sickle cell disease (SCD) may benefit from a variety of disease-modifying therapies, including hydroxyurea, voxelotor, crizanlizumab, L-glutamine, and chronic blood transfusions. However, allogeneic hematopoietic ste
Externí odkaz:
https://doaj.org/article/e54bd1ab4bbc428d8ee87789f68bbc99
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0199375 (2018)
Despite its efficacy, the uptake of HU in adults with sickle cell disease (SCD) is poor likely due to a combination of system, provider, and patient-related factors. We investigated attitudes of adult patients towards HU by conducting qualitative int
Externí odkaz:
https://doaj.org/article/5befaba98d5c461780e5572ddf04617e
Autor:
Nitya Bakshi, Cynthia B Sinha, Diana Ross, Kirshma Khemani, George Loewenstein, Lakshmanan Krishnamurti
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0178413 (2017)
Sickle cell disease (SCD) is an inherited blood disorder that primarily affects African-American and other ethnic minority populations. There are three available disease-modifying therapies for sickle cell disease: hydroxyurea (HU), bone marrow trans
Externí odkaz:
https://doaj.org/article/df81bdb7e16a4355ba79f9863dd6c5ae
Publikováno v:
Pediatric Blood & Cancer. 70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b263ec2ad70c78df03e52b602385c782
https://doi.org/10.1002/pbc.30276
https://doi.org/10.1002/pbc.30276
Autor:
Nitya Bakshi, Rachel Astles, Eric Chou, Asha Hurreh, Soumitri Sil, Cynthia B Sinha, Kolanda Ackey Sanders, Manasa Peddineni, Scott E Gillespie, Rohali Keesari, Lakshmanan Krishnamurti
Publikováno v:
Pediatric Blood & Cancer. 70
There is limited understanding of pain, patient-reported outcomes (PROs) of health-related quality of life (HRQoL), psychological factors, and experimental pain sensitivity before and following hematopoietic cell transplant (HCT) in children with sic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582d572689373a262e4d08a02517c81b
https://doi.org/10.1002/pbc.30046
https://doi.org/10.1002/pbc.30046
Autor:
Anirudh Veludhandi, Diana Ross, Cynthia B Sinha, Courtney McCracken, Nitya Bakshi, Lakshmanan Krishnamurti
BACKGROUND Individuals living with sickle cell disease (SCD) may benefit from a variety of disease-modifying therapies, including hydroxyurea, voxelotor, crizanlizumab, L-glutamine, and chronic blood transfusions. However, allogeneic hematopoietic st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::261bcc1629feba8940f1c5b73816d445
https://doi.org/10.2196/preprints.30093
https://doi.org/10.2196/preprints.30093
Autor:
Lauren M. Hawkins, Cynthia B. Sinha, Diana Ross, Marianne E. M. Yee, Maa-Ohui Quarmyne, Lakshmanan Krishnamurti, Nitya Bakshi
Publikováno v:
BMC Pediatrics, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background There is a limited understanding of the patient and family experience of Chronic Transfusion Therapy (CTT) for prevention of complications of Sickle Cell Disease (SCD). We sought to understand patient and family experience with CT
Externí odkaz:
https://doaj.org/article/f22eeabe491f414b9bb741371a5fbe56